| Document Date: 2014-04-22 11:18:25
Open Document File Size: 203,39 KBShare Result on Facebook
Company National Hemophilia Foundation 2012 Nursing Working Group / New England Journal / ITT / / Country Germany / / IndustryTerm recombinant product / recombinant products / hemophilia care / experimental / factor products / recombinant factor products / / MedicalCondition severe hemophilia A. Journal / moderate hemophilia / hemophilia A / Christmas Disease / disease / mild and moderate hemophilia / severe haemophilia A. Haemophilia / Haemophilia / MILD HEMOPHILIA / traumatic injury / Hemophilia B / routine hemophilia / mild and moderate disease / VIII deficiency / COST OF TREATMENT Hemophilia / severe hemophilia B / nephrotic syndrome / tumor necrosis / mild disease / anaphylactic reactions / infection / moderate disease / expensive disease / deficiency / hemophilia B. In / inflammation / severe disease / thrombosis / Classic hemophilia / IX deficiency / hemophilia / disorders / / MedicalTreatment fibrinolytic therapy / immunizations / bypass / surgery / / Organization National Hemophilia Foundation / FDA / / Person Christine Guelcher / / Product VIII / cyclophosphamide / / ProvinceOrState South Carolina / / PublishedMedium New England Journal of Medicine / / Region New England / / Technology antibodies / /
SocialTag |
Inhibitor Development Christine Guelcher, PNP INTRODUCTION Individuals with hemophilia are deficient in one of the clotting factor proteins that are vital in the formation of a clot. Classic hemophilia or hemophilia A is